A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
Status:
Recruiting
Trial end date:
2022-11-18
Target enrollment:
Participant gender:
Summary
This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of
the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma
(USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for
the management of USC.